Actualités Theralase Technologies Inc - TLT | Actions TSX Venture Exchange

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Theralase® Releases FY2022 Audited Financial Statements

TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”...

Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium

TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”...

Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Company

TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”...

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”...

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”...

Theralase ® Announces Warrant Extension

TORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or “Company”...

Theralase Releases Q322 Interim Financial Statements

TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:...

Theralase® Grants Stock Options

TORONTO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”...

Theralase ® Closes Private Placement Equity Financing

TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”...

Theralase® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing

Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Oct. 03, 2022...

Theralase® Announces Warrant Extension

TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or “Company”...

Theralase® Closes $2.5M Private Placement Equity Financing

TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”...

Theralase Releases Q222 Interim Financial Statements

TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:...

Theralase Expands Intellectual Property Portfolio

TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”...

Theralase® Research - One of the Top 10 Most Downloaded Papers

TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theralase Technologies Inc (TLT)

Outils de qualité professionnelle, pour des investisseurs individuels.

TLT Actualités

Theralase® Releases FY2022 Audited Financial Statements

Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium

Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Company

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

Theralase ® Announces Warrant Extension

Theralase Releases Q322 Interim Financial Statements

Theralase® Grants Stock Options

Theralase ® Closes Private Placement Equity Financing

Theralase® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing

Theralase® Announces Warrant Extension

Theralase® Closes $2.5M Private Placement Equity Financing

Theralase Releases Q222 Interim Financial Statements

Theralase Expands Intellectual Property Portfolio

Theralase® Research - One of the Top 10 Most Downloaded Papers

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theralase Technologies Inc (TLT) Actualités

Theralase Technologies Inc (TLT)

Outils de qualité professionnelle, pour des investisseurs individuels.

TLT Actualités

Theralase® Releases FY2022 Audited Financial Statements

Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium

Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Company

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

Theralase ® Announces Warrant Extension

Theralase Releases Q322 Interim Financial Statements

Theralase® Grants Stock Options

Theralase ® Closes Private Placement Equity Financing

Theralase® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing

Theralase® Announces Warrant Extension

Theralase® Closes $2.5M Private Placement Equity Financing

Theralase Releases Q222 Interim Financial Statements

Theralase Expands Intellectual Property Portfolio

Theralase® Research - One of the Top 10 Most Downloaded Papers

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités